Cargando…
Triple Reuptake Inhibitors: The Next Generation of Antidepressants
Depression has been associated with impaired neurotransmission of serotonergic, norepinephrinergic, and dopaminergic pathways, although most pharmacologic treatment strategies for depression enhance only serotonin and norepinephrine neurotransmission. Current drug development efforts are aimed at a...
Autores principales: | Marks, David M, Pae, Chi-Un, Patkar, Ashwin A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers Ltd.
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2701280/ https://www.ncbi.nlm.nih.gov/pubmed/19587855 http://dx.doi.org/10.2174/157015908787386078 |
Ejemplares similares
-
Triple Reuptake Inhibitors: A Premise and Promise
por: Marks, David M., et al.
Publicado: (2008) -
Serotonin-Norepinephrine Reuptake Inhibitors for Pain Control: Premise and Promise
por: Marks, David M, et al.
Publicado: (2009) -
Does Pregabalin Have Neuropsychotropic Effects?: A Short Perspective
por: Marks, David M., et al.
Publicado: (2009) -
Antidepressant-like Effects of LPM580153, A Novel Potent Triple Reuptake Inhibitor
por: Zhang, Fangxi, et al.
Publicado: (2016) -
Monoaminergic Antidepressants in the Relief of Pain: Potential Therapeutic Utility of Triple Reuptake Inhibitors (TRIs)
por: Hache, Guillaume, et al.
Publicado: (2011)